NCT00209794|UnknownPhase 1/2
IPTi in Mozambican Infants for Malaria Prevention
The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children
Loading search results
The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children
Sponsor study identifier
interventional
1,498
1 country
1
Study Start
September 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
To evaluate if intermittent preventive treatment in infants (IPTi) consisting of SP \[Fansidar\] given through the EPI scheme alongside routine immunisations at 3, 4 and 9 months of age reduces de incidence of clinical malaria up to 12 months of age
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2002
Date type not reportedThis date has not been verified as actual or estimated.
September 13, 2005
Actual (reported)September 21, 2005
Actual (reported)December 2005
Date type not reportedThis date has not been verified as actual or estimated.
Incidence of first or only malaria episodes in each study cohort by 12 months of age.
Incidence of first or only malaria episodes by group up to 12 months of age as per protocol analysis.
Incidence of first or only malaria episodes by group up to 24 months of age.
Incidence of multiple malaria episodes up to 12 months of age.
Incidence of multiple malaria episodes up to 24 months of age.
Incidence of overall and severe anaemia up to 12 months of age.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Centro de Investigaçao em Saude da Manhiça
Manhiça, Maputo Province, Mozambique
Mayor A, Serra-Casas E, Sanz S, Aponte JJ, Macete E, Mandomando I, Puyol L, Berzosa P, Dobano C, Aide P, Sacarlal J, Benito A, Alonso P, Menendez C. Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis. 2008 Jun 15;197(12):1737-42. doi: 10.1086/588144.
Clara Menendez, MD, PhD
Center for International Health, Hospital Clinic de Barcelona
First Submitted
September 13, 2005
First Posted
September 21, 2005
Study Start
September 2002
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
December 2005
Date type not reportedA Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso
Contact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
November 16, 2006
Record last verified: 2006-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: